MAP2K7 and melanoma: Recent study has shown that RSK inhibitors BI-D1870 and BRD7389 significantly reduced the proliferation of BRAF mutant melanoma cells that have acquired resistance to dual BRAF and MEK inhibitor treatment (Theodosakis et al., 2017).